NSCLC
May 04, 2017
Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal
Merck beats Q1 estimates as Keytruda sales double Merck is the victim of its own success, judging from its first-quarter report. The company beat sales and earnings estimates, and it upped its guidance for the year, despite some significant suffering from generic competition. Sales of its hit immuno-oncology drug Ke...
Read More...
Apr 27, 2017
Merck sells biosimilars; AbbVie’s PARP; Pharma heads; Biogen looks to M&A
Merck sells biosimilars business to Fresenius Merck has divested its biosimilars business to fellow German drug maker Fresenius in a deal potentially worth 670 million euros. The drug maker said the move is aligned with a strategy of focusing on innovative medicines while enabling it to exploit its biosimilars portf...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
